186 related articles for article (PubMed ID: 16699266)
21. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human.
Lecci A; Capriati A; Altamura M; Maggi CA
Auton Neurosci; 2006 Jun; 126-127():232-49. PubMed ID: 16616700
[TBL] [Abstract][Full Text] [Related]
22. [Prokinetic agents--their contribution to practice of gastroenterology].
Hep A; Dolina J
Vnitr Lek; 2011 Sep; 57(9):693-6. PubMed ID: 21957760
[TBL] [Abstract][Full Text] [Related]
23. Motilin and ghrelin as prokinetic drug targets.
De Smet B; Mitselos A; Depoortere I
Pharmacol Ther; 2009 Aug; 123(2):207-23. PubMed ID: 19427331
[TBL] [Abstract][Full Text] [Related]
24. Tachykinin receptor antagonists in irritable bowel syndrome.
Lecci A; Valenti C; Maggi CA
Curr Opin Investig Drugs; 2002 Apr; 3(4):589-601. PubMed ID: 12090730
[TBL] [Abstract][Full Text] [Related]
25. Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.
Pasricha PJ
Gastroenterology; 2007 Jun; 132(7):2287-90. PubMed ID: 17570201
[No Abstract] [Full Text] [Related]
26. Are We Close to Targeting Enteric Glia in Gastrointestinal Diseases and Motility Disorders?
Gulbransen BD; Christofi FL
Gastroenterology; 2018 Aug; 155(2):245-251. PubMed ID: 29964042
[No Abstract] [Full Text] [Related]
27. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
28. Prokinetics and fundic relaxants in upper functional GI disorders.
Tack J
Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
[TBL] [Abstract][Full Text] [Related]
29. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments.
Hunt RH; Tougas G
Best Pract Res Clin Gastroenterol; 2002 Dec; 16(6):869-83. PubMed ID: 12473296
[TBL] [Abstract][Full Text] [Related]
30. Access options for withdrawn motility-modifying agents.
Jones MP
Am J Gastroenterol; 2002 Sep; 97(9):2184-8. PubMed ID: 12358230
[TBL] [Abstract][Full Text] [Related]
31. [Motility-modifying drugs].
Storr M; Allescher HD
Internist (Berl); 2000 Dec; 41(12):1318-24, 1326-30. PubMed ID: 11189067
[No Abstract] [Full Text] [Related]
32. Ghrelin as a target for gastrointestinal motility disorders.
Greenwood-Van Meerveld B; Kriegsman M; Nelson R
Peptides; 2011 Nov; 32(11):2352-6. PubMed ID: 21453735
[TBL] [Abstract][Full Text] [Related]
33. Tachykinin receptors and gastrointestinal motility: focus on humans.
Lecci A; Altamura M; Capriati A; Maggi CA
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():69-80. PubMed ID: 18924446
[TBL] [Abstract][Full Text] [Related]
34. Molecular, functional, and pharmacological targets for the development of gut promotility drugs.
Sarna SK
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G545-55. PubMed ID: 16565417
[TBL] [Abstract][Full Text] [Related]
35. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
Sanger GJ; Alpers DH
Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic targets for enteric nervous system disorders.
De Giorgio R; Barbara G; Furness JB; Tonini M
Trends Pharmacol Sci; 2007 Sep; 28(9):473-81. PubMed ID: 17764756
[TBL] [Abstract][Full Text] [Related]
37. [The pharmacological basis of the treatment of disorders of gastrointestinal motility].
Vantrappen G; Hellemans J; Janssens J
Acta Gastroenterol Belg; 1967 Oct; 30(10):646-58. PubMed ID: 5594398
[No Abstract] [Full Text] [Related]
38. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.
Mayer EA; Tillisch K; Bradesi S
Aliment Pharmacol Ther; 2006 Sep; 24(6):919-33. PubMed ID: 16948804
[TBL] [Abstract][Full Text] [Related]
39. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders.
Huizinga JD; Thuneberg L; Vanderwinden JM; Rumessen JJ
Trends Pharmacol Sci; 1997 Oct; 18(10):393-403. PubMed ID: 9357324
[TBL] [Abstract][Full Text] [Related]
40. [Controlled clinical study of a new preparation for the treatment of digestive disorders].
Mereto GC
Minerva Gastroenterol; 1975; 21(1):31-4. PubMed ID: 1207938
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
